Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment

Summary

The aim of this study is to evaluate the financial toxicity reported by Italian patients affected by GEP-NEN during the first year of treatment after diagnosis and its correlations with patient-reported outcomes (PROs) and quality of life (QoL).

Eligibility

Inclusion Criteria:

* ≥18 years of age
* New diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
* Patients who are candidates for surgical and/or medical treatment \[including somatostatin analogues (SAA), peptide recector radionuclide therapy (PRRT), target therapies (everolimus or sunitinib) and chemotherapy\];
* Signed informed consent

Exclusion Criteria:

* Age \< 18 years
* Patients diagnosed with GEP-NEN who are candidates for a surveillance management.
* Patients diagnosed with GEP-NEN who are candidates for best supportive care and/or have a life expectancy \< 6 months.

Conditions2

Browse More Trials